A cost-effective alternative for treating staphylococcal bloodstream infections
Monday, September 21, 2015 - 14:30
in Health & Medicine
Research comparing clinical outcomes between patients receiving nafcillin and cefazolin for treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia shows that overall treatment failure rate among patients receiving cefazolin was no worse than nafcillin, and significantly fewer adverse effects were documented for those receiving cefazolin.